Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the management of cardiovascular adverse events (AEs) associated with long-term or lifelong therapy with tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). Prof. Mauro explains that it is important to risk stratify patients when choosing a frontline therapy to minimize the risk of AEs, and to select more tolerable drugs like asciminib in later treatment lines. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding: Novartis, Bristol Myers Squibb, Sun Pharma/Sparc, Takeda; consultancy: Novartis, Bristol Myers Squibb, Takeda, Pfizer.